Capital & FinanceEvent: August 31, 2026
Partnology notes that Gilead Sciences secured approval for Bixlenvo, a once-daily single-tablet HIV regimen for virologically suppressed adults, extending its lenacapavir franchise.
Published
Signal category
Capital & Finance
Quote
“Gilead Sciences secured approval for #Bixlenvo, a once-daily single-tablet HIV regimen for virologically suppressed adults, including those on complex regimens, extending its lenacapavir franchise”
— Partnology team
Company
Partnology
Building Exciting Biotech Companies
- Industry
- Venture Capital and Private Equity Principals
- Location
- San Diego, US
- Company size
- 4 employees
Partnology is dedicated to the creation and nurturing of nascent biotech companies. Our strategy seamlessly links founders with aligned investors within the Venture Capital ecosystem. Not only do we actively participate in seed round investments, but when deemed beneficial, our executive search team recommends pivotal leadership figures, ensuring the dynamic progression of our partner companies.
Founded 2019